← Scroll for more →
Financial Statements — ADXN
Balance Sheet
(in millions CHF)| Metric | Q2 2025 | Q4 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 2.30 | 3.34 | 3.87 | 7.17 | 6.96 | 8.81 | 20.48 |
| Total Current Assets | 2.66 | 3.54 | 4.23 | 8.69 | 7.83 | 10.95 | 21.94 |
| Total Non-current Assets | 5.85 | 7.14 | 0.41 | 0.31 | 0.45 | 0.44 | 0.60 |
| Total Assets | 8.51 | 10.68 | 4.64 | 9.00 | 8.28 | 11.38 | 22.54 |
| Total Current Liabilities | 1.15 | 0.80 | 2.89 | 2.71 | 3.28 | 4.30 | 4.13 |
| Total Non-current Liabilities | 0.14 | 0.20 | 0.60 | 0.16 | 0.09 | 0.22 | 1.48 |
| Total Liabilities* | 1.29 | 1.00 | 3.50 | 2.87 | 3.37 | 4.52 | 5.61 |
| Retained Earnings | (356.68) | (353.36) | (360.42) | (354.94) | (349.86) | (342.10) | (329.06) |
| Total Stockholder Equity | 7.21 | 9.68 | 1.15 | 6.13 | 4.91 | 6.86 | 16.93 |
← Scroll for more columns →
* Derived from reported values
Income Statement
(in millions CHF) (except per-share rows)| Metric | Q2 2025 | Q2 2023 | Q2 2022 |
|---|---|---|---|
| Total Revenue | 0.12 | 0.63 | 0.18 |
| Research & Development | 0.23 | 1.88 | 5.75 |
| Selling, General & Admin | 0.53 | 1.30 | 1.53 |
| Total Operating Expenses | 0.77 | 3.18 | 7.28 |
| Operating Income | (0.73) | (2.55) | (7.09) |
| Interest Expense | 0.00 | 0.00 | 0.01 |
| Pretax Income | (1.96) | (2.68) | (7.22) |
| Tax Provision | -- | 0.00 | -- |
| Net Income | (1.84) | (2.68) | (7.22) |
| Basic EPS | (0.02) | (0.04) | (0.19) |
| Diluted EPS | (0.02) | (0.04) | (0.19) |
← Scroll for more columns →
Cash Flow Statement
(in millions CHF)| Metric | Q2 2025 | Q2 2023 | Q2 2022 |
|---|---|---|---|
| Operating Cash Flow | (1.02) | (5.12) | (10.67) |
| Investing Cash Flow | (0.74) | -0.00 | (0.01) |
| Financing Cash Flow | 0.75 | 5.51 | (0.91) |
← Scroll for more columns →